Your browser doesn't support javascript.
loading
Complementary and Alternative Medicine for Gliomas: Systematic Review and Critical Appraisal of Current Literature.
Kerezoudis, Panagiotis; Kerezoudi, Evangelia N; Choudhry, Abdurehman; Himes, Benjamin T; Parney, Ian F.
Afiliación
  • Kerezoudis P; Department of Neurologic Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
  • Kerezoudi EN; School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Choudhry A; The Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Himes BT; Department of Neurologic Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
  • Parney IF; Department of Neurologic Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Neurosurgery ; 92(3): 464-471, 2023 03 01.
Article en En | MEDLINE | ID: mdl-36650046
ABSTRACT

BACKGROUND:

Many patients with glioma and their caregivers seek complementary and alternative medicine (CAM) methods to comfort themselves, cope with cancer medication side effects, and feel they are taking control of their disease.

OBJECTIVE:

To summarize existing evidence on safety and efficacy of CAM treatments for gliomas.

METHODS:

We performed an exhaustive electronic literature search for in vitro, animal, and clinical studies (English language, all years available) on CAM modalities for gliomas.

RESULTS:

A total of 378 studies (315 unique articles) were analyzed. Distribution was as follows in vitro-274 (73%), animal-77 (20%), and clinical-26 (7%, 2491 patients). Most studies were conducted in China (n = 135, 43%), followed by the United States (n = 62, 20%) and Spain (n = 17, 5%-6%). Resveratrol was the most commonly investigated CAM therapy in the in vitro (n = 62) and in vivo (n = 17) setting. Safety/toxicity was examined in 21% of in vitro (cytotoxic at same dose in 48%), 39% of in vivo (no evidence of organ toxicity), and 50% of clinical studies (adverse events reported in 6). Cytotoxicity was the most frequent end point among in vitro (60%) and animal studies (56%), followed by synergistic action with chemotherapy and inhibition of invasiveness and migration. Finally, 7 of 26 studies found no clinical effect, whereas 5 reported possible impact on progression-free or overall survival, 3 demonstrated decrease or arrest of tumor progression, and 2 showed positive impact on symptoms and quality of life.

CONCLUSION:

These findings will hopefully educate providers and patients and stimulate further research in the field of CAM therapy for gliomas.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapias Complementarias / Glioma / Antineoplásicos Tipo de estudio: Systematic_reviews Aspecto: Patient_preference Límite: Humans País/Región como asunto: America do norte / Asia Idioma: En Revista: Neurosurgery Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapias Complementarias / Glioma / Antineoplásicos Tipo de estudio: Systematic_reviews Aspecto: Patient_preference Límite: Humans País/Región como asunto: America do norte / Asia Idioma: En Revista: Neurosurgery Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos